Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimized p53 immunohistochemistry is an accurate predictor of <i>TP53</i> mutation in ovarian carcinoma

9 Jun 2016

Abstract excerpt

Abstract TP53 mutations are ubiquitous in high‐grade serous ovarian carcinomas (HGSOC), and the presence of TP53 mutation discriminates between high and low‐grade serous carcinomas and is now an important biomarker for clinical trials targeting mutant p53. p53 immunohistochemistry (IHC) is widely used as a surrogate for TP53 mutation but its accuracy has not been established. The objective of this study was to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer-related Molecular Pathways
Share to Ovarian cancer diagnosis and treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27840695
DOI: 10.1002/cjp2.53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimized p53 immunohistochemistry is an accurate predictor of <i>TP53</i> mutation in ovarian carcinomaPMID 27840695Read ↗

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.Semantic proximity Read ↗

Refined criteria for p53 expression in ovarian mucinous tumours are highly concordant with TP53 mutation status, but p53 expression/TP53 status lack prognostic significance.Semantic proximity Read ↗

Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.Semantic proximity Read ↗

TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.Semantic proximity Read ↗

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)Semantic proximity Read ↗

Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas.Semantic proximity Read ↗

Detecting TP53 mutations in paired liquid and tissue biopsies from patients with high-grade serous ovarian carcinoma.Semantic proximity Read ↗

TP53 mutations in epithelial ovarian cancerSemantic proximity Read ↗

Correlation analysis of TP53 missense mutations and p53 protein expression patterns in endometrial carcinoma.Semantic proximity Read ↗

P53 immunohistochemistry is an ideal surrogate marker for TP53 mutation and a predictor of early metastasis in breast cancer: Real-world analysisSemantic proximity Read ↗

Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.Semantic proximity Read ↗

The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.